Skip to main content

Table 4 List of any cancer (and breast cancer) related genes and unique variants identified by individual patients in the control group. The strength of known association of each variant with oncogenesis is marked as known (**), potential (*) or no (no marker)

From: Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden

BC only patients (no. of SNPs)

Gene (known breast cancer gene)

SNP

Effect of mutation *- potential **- known association

T-1 (3)

ATM

c.8965C > G

p.Gln2989Glu*

MUTYH

c.1435G > A

p.Glu479Lys*

FANCB

c.2435A > G

p.Tyr812Cys*

T-2 (2)

MSR1

c.919G > T

p.Asp307Tyr*

ATM

c.6067G > A

p.Gly2023Arg

T-3 (4)

RAD50

c.1741C > T

p.His581Tyr*

MITF

c.1255G > T

p.Glu419Ter**

WRN

c.95A > G

p.Lys32Arg

APC

c.7490C > T

p.Ser2497Leu

T-4 (6)

ELANE

c.341 T > C

p.Leu114Ser*

RB1

c.10A > C

p.Lys4Gln*

WRN

c.1149G > T

p.Leu383Phe

ERCC4

c.1135C > T

p.Pro379Ser

MSR1

c.667 T > A

p.Ser223Thr*

WRN

c.2983G > A

p.Ala995Thr

T-5 (1)

TSC1

c.1390G > A

p.Gly464Ser*

T-6 (1)

CHEK2

c.190G > A

p.Glu64Lys**

T-7 (3)

MSH2

c.2187G > A

p.Met729Ile*

RAD50

c.734A > G

p.Glu245Gly*

FANCA

c.2658G > C

p.Glu886Asp*

T-8 (2)

CDH1

c.344C > T

p.Thr115Met*

MET

c.2962C > T

p.Arg988Cys

T-9 (6)

MDH2

c.415G > A

p.Val139Ile*

FANCA

c.1874G > C

p.Cys625Ser

ATR

c.7303A > G

p.Ile2435Val*

TERT

c.2726 T > C

p.Val909Ala*

PALB2

c.2483G > A

p.Cys828Tyr*

FANCB

c.454 T > C

p.Phe152Leu*

T-10 (3)

RECQL4

c.616A > C

p.Lys206Gln*

BLM

c.3536C > T

p.Thr1179Ile*

FANCC

c.632C > G

p.Pro211Arg

T-11 (3)

MITF

c.1334C > A

p.Thr445Lys

WRN

c.1211 T > C

p.Ile404Thr

SLX4

c.179A > C

p.Gln60Pro

T-12 (1)

FANCI

c.824 T > C

p.Ile275Thr

T-13 (3)

BUB1

c.307A > G

p.Ile103Val

FANCA

c.1874G > C

p.Cys625Ser

AXIN2

c.1994delG

p.Gly665fs*

T-14 (3)

RECQL4

c.941C > T

p.Pro314Leu

SLX4

c.4963A > G

p.Arg1655Gly

RAD51C

c.130 T > C

p.Ser44Pro

T-15 (1)

PMS1

c.1609G > A

p.Glu537Lys*